Proteometabolomics of bladder cancer: Current and future prospects

Cancer Biomarkers

Volumn 15, Issue 4, 2015, Pages 339-348

  Bansal, Navneeta ^a   Gupta, Ashish ^b   Sankhwar, Satya Narain ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bladder cancer; FDA; metabolomics; proteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; BLADDER TUMOR ANTIGEN; CYSTATIN B; CYTOKERATIN; CYTOKERATIN 10; CYTOKINE; DEFENSIN; FAS ANTIGEN; FIBRINOGEN DEGRADATION PRODUCT; GLYCOPROTEIN; GLYCOSYLATED PROTEIN; HEAT SHOCK PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN; NUCLEAR MATRIX PROTEIN 22; POLYPEPTIDE; PROFILIN; PROFILIN 1; REGENERATING PROTEIN 1; SERINE PROTEINASE; SURVIVIN; SYNAPSIN I; TUMOR ANTIGEN; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TUMOR MARKER; UNCLASSIFIED DRUG; UROPLAKIN; UROPLAKIN 3A; PROTEOME;

BLADDER CANCER; BLOOD ANALYSIS; CANCER PATIENT; CELL NUCLEUS MATRIX; HUMAN; MASS SPECTROMETRY; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; URINALYSIS; BLADDER TUMOR; BLOOD; FOOD AND DRUG ADMINISTRATION; GENETICS; PATHOLOGY; UNITED STATES;

BIOMARKERS, TUMOR; HUMANS; METABOLOMICS; PROTEOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URINARY BLADDER NEOPLASMS;

EID: 84931085438     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150479     Document Type: Review

References (96)

1. Jemal R, Siegel, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Salehi AA, Khezri L, Minsharifi MA. Epidemiologic status of bladder cancer in Shiraz, Southern Iran. Asian Pacific J. Cancer Prev 2011; 12: 1323-1327.
3. Reuter VE. The pathology of bladder cancer. J Uro 2006; 67(3) S1: 11-17.
4. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Onco 2010; 28(4): 429-440.
5. Badalament RA, Hermansen DK, Kimmel M, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987; 60: 1423-1427.
6. Konety BR. Molecular markers in bladder cancer: A critical appraisal. Urol Onco: Semi and Origl Invest 2006; 24: 326-337.
7. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev in Uro 2008; 10: 120-135.
8. Nicholson JK, Connelly J, Lindon J C et al. Metabonomics: A platform for studing drug toxicity and gene function. Nature Reviews Drug Discovery 2002; 1: 153-161.
9. Nicholson J. Global systems biology, personalized medicine and molecular epidemiology. Editorial. Mol Sys Biol 2006; 1-6.
10. Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40 (1): 387-426.
11. Greef VDJ, Stroobant P, Heijden VDR. The role of analytical sciences medical systems biology. Curr Opin in Chem Biol 2004; 8(5): 559-565.
12. Smolinska A, blanchet L, Buydens LMC et al. NMR and pattern recognition methods in metabolomics: From data acquisition to biomarker discovery; A review. Anal Chem Acta 2012; 750: 82-97.
13. Wood SL, Knowles MA, Thompson D et al. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nature Reviews Urology 2013; 10: 206-218.
14. Nilofer S. Azad NS, Rasool N, Annunziata CM et al. Proteomics in clinical trials and practice. Molecular & Cellular Proteomics 2006; 5: 1819-1829.
15. Issaq HJ, Nativ O, Waybright T, et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008; 179: 2422-2426.
16. Srivastava S, Roy R, Singh S, et al. Taurine - a possible fingerprint biomarker in non-muscle-invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark 2010; 6: 11-20.
17. Pasikanti KK, Esuvaranathan K, Ho PC, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 2010; 9: 2988-95.
18. Kim JW, Lee G, Moon SM, et al. Metabolomic screening and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients. Metabolomics 2010; 6: 202-206.
19. Huang Z, Lin L, Gao Y, et al. Bladder cancer determination via two urinary metabolites: A biomarker pattern approach. Mol Cell Prot 2011; 10(10): M111.007922-1-M111.007922-10.
20. Cao M, Zhao L, Haigo C, et al. NMR-based metabolomics analysis of human bladder cancer. Anal Sci 2012; 28: 451-456.
21. Bansal N, Gupta A, Mitash N et al. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J. Proteome Res 2013; 12: 5839-5850.
22. Rosser CJ, Urquidi V, Goodison S. Urinary biomarkers of bladder cancer: An update and future perspectives. Biomarkers Med 2013; 7(5): 779-790.
23. Van Rhijn BW, Van der Poel HG, Van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47(6): 736-748.
24. Sarosdy M, Hudson M, and Ellis W, et al. Improved detection of recurrent bladder cancer using the Bard BTA-Stat test. Urology 1997; 50: 349-353.
25. Mattioli S, Seregnis E, and Caperna L. BTA Trak combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma of the bladder. Int J Biol Markers 2000; 15: 219-225.
26. Heicappall R, Weetig I, Schostak M, et al. Quantitative detection of human complement factor H related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999; 35: 81-87.
27. Marcus horstmann. Currently available urine-based tumour markers in the detection of new and recurrent urothelial bladder cancer. Nephro-Urol Mon 2012; 4(1): 345-349.
28. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 2004; 64(4): 687-692.
29. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974; 60(4): 1410-1417.
30. Grossman H, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810-816.
31. Ponsky LE, Sharma S, Pandrangi L, et al. Screening and monitoring for bladder cancer: Refining the use of NMP22. J Urol 2001; 166(1): 75-78.
32. Yokoyama T, Sekigawa R, Hayashi T, et al. The clinical efficacy of Bladder Chek NMP22 in urothelial cancer. Rinsho Byori 2004; 52(3): 199-203.
33. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993; 11: 145-153.
34. Lodde M, Mian C, Comploj E, et al. uCyt? test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006; 67(5): 950-954.
35. Messing EM, Teot L, Korman H, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: A multicenter study in the United States. J Urol 2005; 174(4 Pt 1): 1238-41.
36. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-611.
37. Grossman HB, Washington RW, Carey TE, et al. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl 1992; 16I: 63-68.
38. Sawczuk IS, Pickens CL, Vasa UR, et al. DD23 Biomarker: A prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002; 7: 185-190.
39. Wajsman Z, Williams PD, Greco J, et al. Further study of fibrinogen degradation products in bladder cancer detection. Urology 1978; 12: 659-661.
40. Schmetter BS, Habicht KK, Lamm DL, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol 1997; 158: 801-805.
41. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J. Urol 1999; 161; 388-394.
42. Lokeshwar VB, Soloway MS. Current bladder tumor test: Does their projected utility fulfill clinical necessity. Urol 2001; 165 (4): 1067-1077.
43. Topsakal M, Karadeniz T, Anac M, et al. Assessment of fibrinfibrinogen degradation products (accu-dx) test in bladder cancer patients. Eur Urol 2001; 39: 287-291.
44. Bassi P, Marangi F, Volpe A, et al. Markers for urological malignancies. Eur Urol Rev 2010; 5: 36-43.
45. Pode D, Golijanin D, Sherman Y, et al. Immunostaining of Lewis X in cells from voided urine, cytopathology, and ultrasound for noninvasive detection of bladder tumors. J. Urol 1998; 159: 389-393.
46. Planz B, Striepecke E, Jakse G, et al. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder. J. Urol 1998; 159: 384-388.
47. Sheinfeld J, Reuter VE, Melamed MR, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143: 285-288.
48. Rhijn VBW, Poel VDHG, Kwast VDTH. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005; 47(6): 736-748.
49. Weikert S, Christoph F, Schrader M, et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005; 116: 100-104.
50. Robert H. Getzenberg RH, Konety BR, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56: 1690-1694.
51. Van Le T, Miller R, Barder T, et al. Gertzenberg R. Highly specific urine-based marker of bladder cancer. Urology 2005; 66: 1256-60.
52. Tetu B, Tiguert R, Harel F, et al. ImmunoCyt/uCyt? improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005; 18(1): 83-9.
53. Horstmann M, Bontrup H, Hennenlotter J, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J. Urol 2010; 28(3): 399-404.
54. Moussa O, Abol-Enein H, Bissada N, et al. Evaluation of survivin reverse transcriptasepolymerase chain reaction for non-invasive detection of bladder cancer. J Urol 2006; 175: 2312-2316.
55. Holterman DA, Diaz JI, Blackmore PF et al. Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol; 2006: 24, 97-108.
56. Vlahou A, Schellhammer PF Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. American Journal of Pathology; 2001; 158 (4): 1491-1502.
57. Svatek RS, Herman MP, Lotan Y, et al. Soluble Fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006; 106: 1701-1707.
58. Yang H, Li H, Wang Z, et al. Is Urinary Soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A Prospective Chart Study. Urol Int 2013; 91: 456-461.
59. Mizutani Y, Yoshida O, Ukimura O, et al. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm 2002; 17: 563-567.
60. Perabo FG, Mattes RH, Wirger A, et al. Soluble Fas and Fasligand in bladder cancer in vitro and in vivo. Urol Oncol 2001; 6: 163-169.
61. Stoeber K, Swinn R, Prevost AT, et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002; 94: 1071-1079.
62. Kelly JD, Dudderidge TJ, Wollenschlaeger A. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22. PLoS One 2012; 7: e40305.
63. http://www.urosens.com/urosens-receives-0-5-million-funding-and-enters-into-clinical-trials-for-bladder-cancerdiagnostic/.
64. Irmak S, Tilki D, Heukeshoven J, et al. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005; 5: 4296-304.
65. Ritter R, Hennenlotter J, Kühs U, et al. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Onco: Semi and Orig Invest 2014; 32: 337-344.
66. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: Current developments and future implementation. Curr Opin Urol 2007; 17: 341-346.
67. Benedict WF, Fisher M, Zhang XQ, et al. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNa/Syn3 treatment in a phase l study. Cancer Gene Therapy 2014; 21: 91-94.
68. Pinero OE, Corton M, Peramato GP, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res 2007; 6: 4440-4448.
69. Feldman AS, Banyard J, Wu CL, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009; 15: 1024-1031.
70. Lei Y, Ye J, Chen J. UPK3a. A promising novel urinary marker for detection of bladder cancer. Uro 2010; 76: 514. e6-514. e-11.
71. Chen CL, Lai YF, Tang P, et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 2012; 11: 5611-5629.
72. Zoidakis J, Makridakis M, Zerefos PJ et al. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Pro 2012; 11(4): M111.009449-1-M111.009449-15.
73. Lorenzi T, Lorenzi M, Altobelli E, et al. HtrA1 in human urothelial bladder cancer: A secreted protein and a potential novel biomarker. Int J Cancer 2013; 133: 2650-2661.
74. Zhang YF, Wu DL, Guan M et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clinical Biochemistry 2004; 37: 772-779.
75. Iwaki H, Kageyama S, Isono T. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Can Sci 2004; 95 (12): 955-961.
76. Rosser CJ, Ross S, Chang M, et al. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol 2013; 190: 2257-2262.
77. Saitoa M, Kimotoa M, Araki T, et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Euro Uro 2005; 48: 865-871.
78. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. Plos 2012; 7 (10): e47469.
79. Theodorescu, D. Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lan Oncol 2006; 7: 230-240.
80. Schiffer E, Vlahou A, Petrolekas A et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res 2009; 15: 4935-4943.
81. Chen YT, Chen CL, Chen HW, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using itraq technology. J of Pro Res 2010; 9: 5803-5815.
82. Chen CL, Linc TS, Tsaid CH, et al. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J of Proteomics 2013; 85: 28-43.
83. Margel D, Fischer MP, Baniel J et al. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Euro Urol 2011; 59: 113-119.
84. Chena YT, Chena HW, Domanskic D et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J of Pro 2012; 75(12): 3529-3545.
85. Linden M, Lind SB, Mayrhofer C et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 2012; 12: 135-144.
86. Linden M, Segersten U, Runeson M et al. Tumour expression of bladder cancer-associated urinary proteins. BJU Int 2013; 112: 407-415.
87. Yang N, Feng S, Shedden K, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011; 17: 3349-3359.
88. Urquidi V, Goodison S, Ross S, et al. Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol 2012b; 188: 2377-2383.
89. Yao R, Davidson DD, Lopez-Beltran A, et al. The S100 proteins for screening and prognostic grading of bladder cancer. Histo Histopathol 2007; 22(9): 1025-32.
90. Agerbeak M, Alsner J, Marcussen N, et al. Focal s100a4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patient. Eur Urol 2006; 50(4): 777-785.
91. Minami S, Sato Y, Matsumoto T, et al. Proteomic study of sera from patients with bladder cancer: Usefulness of S100A8 and S100A9 proteins. Can Geno Pro 2010; 7: 181-190.
92. Bansal N, Gupta A, Sankhwar N et al. Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. Clinica Chimica Acta 2014; 436: 97-103.
93. Ecke TH, Schlechte HH, Schulze G. Four tumour markers for urinary bladder cancer - tissue polypeptide antigen (tpa), her-2/neu (erb b2), urokinase-type plasminogen activator receptor (upar) and tp53 mutation. Antican Res 2005; 25: 635-642.
94. Schwamborn K, Krieg RC, Grosse J, et al. Serum proteomic profiling in patients with bladder cancer. Eur Uro 2009; 56: 989-997.
95. Abogunrin F, Kane HFO, Ruddock MW et al. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 2012; 118(10): 2641-2650.
96. Lee YR, Chen YW, Tsai MC, et al. Redox- and expression-proteomic analysis of plasma biomarkers in bladder transitional cell carcinoma. Mol Bio Syst 2012; 8: 3314-3324.